We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Revolutionary AI Tool Transforms Disease Visualization

By LabMedica International staff writers
Posted on 10 Feb 2025
Print article
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere with this process and cause disease. Omics refers to the study of genes, proteins, and other molecular data to explore the body's functions and how diseases evolve. Now, an artificial intelligence (AI) tool is assisting in converting vast, complex biological data into two-dimensional circular visuals. By mapping this data, the tool might offer clinicians and researchers a novel method for visualizing disease patterns, such as those found in cancer and neurological disorders, which could aid in directing personalized treatments. Additionally, it may provide an intuitive means of exploring disease mechanisms and interactions.

Developed by researchers at Mayo Clinic (Rochester, MN, USA), the tool called OmicsFootPrint helps to clarify these complexities by transforming data—such as gene activity, mutations, and protein levels—into vibrant, circular maps that offer a clearer understanding of what’s occurring within the body. In their study, the researchers employed OmicsFootPrint to examine drug responses and cancer multi-omics data. The tool successfully distinguished between two types of breast cancer—lobular and ductal carcinomas—with an average accuracy of 87%. In lung cancer, it showed over 95% accuracy in identifying two types: adenocarcinoma and squamous cell carcinoma. The findings, published in Nucleic Acids Research, revealed that combining various types of molecular data yields more accurate results than using just a single type.

The OmicsFootPrint also demonstrates promise in generating meaningful insights even with limited datasets. It utilizes advanced AI techniques that learn from existing data and apply this knowledge to new situations, a process known as transfer learning. For instance, it assisted researchers in achieving over 95% accuracy in identifying lung cancer subtypes with less than 20% of the usual data volume. To further enhance its accuracy and insights, the OmicsFootPrint framework incorporates a sophisticated method called SHAP (SHapley Additive exPlanations). SHAP highlights the key markers, genes, or proteins that impact the results, aiding researchers in understanding the underlying factors driving disease patterns. In addition to research, OmicsFootPrint is also intended for clinical use. It compresses large biological datasets into compact images that occupy only 2% of the original storage space. This compression could simplify the integration of the images into electronic medical records, potentially guiding future patient care. The research team is working on expanding OmicsFootPrint to explore additional diseases, including neurological conditions and other complex disorders. They are also focusing on updates to enhance the tool's accuracy and flexibility, such as the ability to identify new disease markers and drug targets.

"Data becomes most powerful when you can see the story it's telling," says Krishna Rani Kalari, Ph.D., lead author of the study and associate professor of biomedical informatics at Mayo Clinic's Center for Individualized Medicine. "The OmicsFootPrint could open doors to discoveries we haven't been able to achieve before."

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.